A citation-based method for searching scientific literature

Emmanuel S Antonarakis, Changxue Lu, Hao Wang, Brandon Luber, Mary Nakazawa, Jeffrey C Roeser, Yan Chen, Tabrez A Mohammad, Yidong Chen, Helen L Fedor, Tamara L Lotan, Qizhi Zheng, Angelo M De Marzo, John T Isaacs, William B Isaacs, Rosa Nadal, Channing J Paller, Samuel R Denmeade, Michael A Carducci, Mario A Eisenberger, Jun Luo. N Engl J Med 2014
Times Cited: 1620







List of co-cited articles
698 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Increased survival with enzalutamide in prostate cancer after chemotherapy.
Howard I Scher, Karim Fizazi, Fred Saad, Mary-Ellen Taplin, Cora N Sternberg, Kurt Miller, Ronald de Wit, Peter Mulders, Kim N Chi, Neal D Shore,[...]. N Engl J Med 2012
32

Integrative clinical genomics of advanced prostate cancer.
Dan Robinson, Eliezer M Van Allen, Yi-Mi Wu, Nikolaus Schultz, Robert J Lonigro, Juan-Miguel Mosquera, Bruce Montgomery, Mary-Ellen Taplin, Colin C Pritchard, Gerhardt Attard,[...]. Cell 2015
25

Abiraterone and increased survival in metastatic prostate cancer.
Johann S de Bono, Christopher J Logothetis, Arturo Molina, Karim Fizazi, Scott North, Luis Chu, Kim N Chi, Robert J Jones, Oscar B Goodman, Fred Saad,[...]. N Engl J Med 2011
24

Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer.
Adam Sharp, Ilsa Coleman, Wei Yuan, Cynthia Sprenger, David Dolling, Daniel Nava Rodrigues, Joshua W Russo, Ines Figueiredo, Claudia Bertan, George Seed,[...]. J Clin Invest 2019
139
23

Enzalutamide in metastatic prostate cancer before chemotherapy.
Tomasz M Beer, Andrew J Armstrong, Dana E Rathkopf, Yohann Loriot, Cora N Sternberg, Celestia S Higano, Peter Iversen, Suman Bhattacharya, Joan Carles, Simon Chowdhury,[...]. N Engl J Med 2014
22

Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer.
Rong Hu, Thomas A Dunn, Shuanzeng Wei, Sumit Isharwal, Robert W Veltri, Elizabeth Humphreys, Misop Han, Alan W Partin, Robert L Vessella, William B Isaacs,[...]. Cancer Res 2009
717
20

Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer.
Howard I Scher, David Lu, Nicole A Schreiber, Jessica Louw, Ryon P Graf, Hebert A Vargas, Ann Johnson, Adam Jendrisak, Richard Bambury, Daniel Danila,[...]. JAMA Oncol 2016
404
19

Genomic correlates of clinical outcome in advanced prostate cancer.
Wassim Abida, Joanna Cyrta, Glenn Heller, Davide Prandi, Joshua Armenia, Ilsa Coleman, Marcin Cieslik, Matteo Benelli, Dan Robinson, Eliezer M Van Allen,[...]. Proc Natl Acad Sci U S A 2019
319
19

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
Matthew R Smith, Fred Saad, Simon Chowdhury, Stéphane Oudard, Boris A Hadaschik, Julie N Graff, David Olmos, Paul N Mainwaring, Ji Youl Lee, Hiroji Uemura,[...]. N Engl J Med 2018
526
18

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.
Maha Hussain, Karim Fizazi, Fred Saad, Per Rathenborg, Neal Shore, Ubirajara Ferreira, Petro Ivashchenko, Eren Demirhan, Katharina Modelska, De Phung,[...]. N Engl J Med 2018
441
16

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.
Karim Fizazi, Neal Shore, Teuvo L Tammela, Albertas Ulys, Egils Vjaters, Sergey Polyakov, Mindaugas Jievaltas, Murilo Luz, Boris Alekseev, Iris Kuss,[...]. N Engl J Med 2019
303
15

Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study.
Andrew J Armstrong, Susan Halabi, Jun Luo, David M Nanus, Paraskevi Giannakakou, Russell Z Szmulewitz, Daniel C Danila, Patrick Healy, Monika Anand, Colin J Rothwell,[...]. J Clin Oncol 2019
150
14

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
Karim Fizazi, NamPhuong Tran, Luis Fein, Nobuaki Matsubara, Alfredo Rodriguez-Antolin, Boris Y Alekseev, Mustafa Özgüroğlu, Dingwei Ye, Susan Feyerabend, Andrew Protheroe,[...]. N Engl J Med 2017
925
14

Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade.
Vivek K Arora, Emily Schenkein, Rajmohan Murali, Sumit K Subudhi, John Wongvipat, Minna D Balbas, Neel Shah, Ling Cai, Eleni Efstathiou, Chris Logothetis,[...]. Cell 2013
544
14

Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
Emmanuel S Antonarakis, Changxue Lu, Brandon Luber, Hao Wang, Yan Chen, Mary Nakazawa, Rosa Nadal, Channing J Paller, Samuel R Denmeade, Michael A Carducci,[...]. JAMA Oncol 2015
429
13

Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer.
Howard I Scher, Ryon P Graf, Nicole A Schreiber, Anuradha Jayaram, Eric Winquist, Brigit McLaughlin, David Lu, Martin Fleisher, Sarah Orr, Lori Lowes,[...]. JAMA Oncol 2018
130
13

Olaparib for Metastatic Castration-Resistant Prostate Cancer.
Johann de Bono, Joaquin Mateo, Karim Fizazi, Fred Saad, Neal Shore, Shahneen Sandhu, Kim N Chi, Oliver Sartor, Neeraj Agarwal, David Olmos,[...]. N Engl J Med 2020
405
13

Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide.
Emmanuel S Antonarakis, Changxue Lu, Brandon Luber, Hao Wang, Yan Chen, Yezi Zhu, John L Silberstein, Maritza N Taylor, Benjamin L Maughan, Samuel R Denmeade,[...]. J Clin Oncol 2017
267
12

Abiraterone in metastatic prostate cancer without previous chemotherapy.
Charles J Ryan, Matthew R Smith, Johann S de Bono, Arturo Molina, Christopher J Logothetis, Paul de Souza, Karim Fizazi, Paul Mainwaring, Josep M Piulats, Siobhan Ng,[...]. N Engl J Med 2013
12

A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth.
Zhiyong Guo, Xi Yang, Feng Sun, Richeng Jiang, Douglas E Linn, Hege Chen, Hegang Chen, Xiangtian Kong, Jonathan Melamed, Clifford G Tepper,[...]. Cancer Res 2009
617
12

Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.
Rong Hu, Changxue Lu, Elahe A Mostaghel, Srinivasan Yegnasubramanian, Meltem Gurel, Clare Tannahill, Joanne Edwards, William B Isaacs, Peter S Nelson, Eric Bluemn,[...]. Cancer Res 2012
394
12

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.
Ian D Davis, Andrew J Martin, Martin R Stockler, Stephen Begbie, Kim N Chi, Simon Chowdhury, Xanthi Coskinas, Mark Frydenberg, Wendy E Hague, Lisa G Horvath,[...]. N Engl J Med 2019
396
12

Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
James L Mohler, Emmanuel S Antonarakis, Andrew J Armstrong, Anthony V D'Amico, Brian J Davis, Tanya Dorff, James A Eastham, Charles A Enke, Thomas A Farrington, Celestia S Higano,[...]. J Natl Compr Canc Netw 2019
506
11

Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
Nicholas D James, Johann S de Bono, Melissa R Spears, Noel W Clarke, Malcolm D Mason, David P Dearnaley, Alastair W S Ritchie, Claire L Amos, Clare Gilson, Rob J Jones,[...]. N Engl J Med 2017
792
11

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.
Karim Fizazi, Howard I Scher, Arturo Molina, Christopher J Logothetis, Kim N Chi, Robert J Jones, John N Staffurth, Scott North, Nicholas J Vogelzang, Fred Saad,[...]. Lancet Oncol 2012
867
11

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.
Charles J Ryan, Matthew R Smith, Karim Fizazi, Fred Saad, Peter F A Mulders, Cora N Sternberg, Kurt Miller, Christopher J Logothetis, Neal D Shore, Eric J Small,[...]. Lancet Oncol 2015
754
11

Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.
Arun A Azad, Stanislav V Volik, Alexander W Wyatt, Anne Haegert, Stephane Le Bihan, Robert H Bell, Shawn A Anderson, Brian McConeghy, Robert Shukin, Jenny Bazov,[...]. Clin Cancer Res 2015
303
11

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.
Johann S de Bono, Howard I Scher, R Bruce Montgomery, Christopher Parker, M Craig Miller, Henk Tissing, Gerald V Doyle, Leon W W M Terstappen, Kenneth J Pienta, Derek Raghavan. Clin Cancer Res 2008
11


Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
10

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
Kim N Chi, Neeraj Agarwal, Anders Bjartell, Byung Ha Chung, Andrea J Pereira de Santana Gomes, Robert Given, Álvaro Juárez Soto, Axel S Merseburger, Mustafa Özgüroğlu, Hirotsugu Uemura,[...]. N Engl J Med 2019
363
10

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
Christopher J Sweeney, Yu-Hui Chen, Michael Carducci, Glenn Liu, David F Jarrard, Mario Eisenberger, Yu-Ning Wong, Noah Hahn, Manish Kohli, Matthew M Cooney,[...]. N Engl J Med 2015
10

Molecular determinants of resistance to antiandrogen therapy.
Charlie D Chen, Derek S Welsbie, Chris Tran, Sung Hee Baek, Randy Chen, Robert Vessella, Michael G Rosenfeld, Charles L Sawyers. Nat Med 2004
10

Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Chris Tran, Samedy Ouk, Nicola J Clegg, Yu Chen, Philip A Watson, Vivek Arora, John Wongvipat, Peter M Smith-Jones, Dongwon Yoo, Andrew Kwon,[...]. Science 2009
10

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Ian F Tannock, Ronald de Wit, William R Berry, Jozsef Horti, Anna Pluzanska, Kim N Chi, Stephane Oudard, Christine Théodore, Nicholas D James, Ingela Turesson,[...]. N Engl J Med 2004
10

Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.
Himisha Beltran, Davide Prandi, Juan Miguel Mosquera, Matteo Benelli, Loredana Puca, Joanna Cyrta, Clarisse Marotz, Eugenia Giannopoulou, Balabhadrapatruni V S K Chakravarthi, Sooryanarayana Varambally,[...]. Nat Med 2016
708
10

Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival.
Emma Hörnberg, Erik Bovinder Ylitalo, Sead Crnalic, Henrik Antti, Pär Stattin, Anders Widmark, Anders Bergh, Pernilla Wikström. PLoS One 2011
336
10

Cancer statistics, 2020.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2020
10

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.
Howard I Scher, Michael J Morris, Walter M Stadler, Celestia Higano, Ethan Basch, Karim Fizazi, Emmanuel S Antonarakis, Tomasz M Beer, Michael A Carducci, Kim N Chi,[...]. J Clin Oncol 2016
618
9

Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.
Yingming Li, Siu Chiu Chan, Lucas J Brand, Tae Hyun Hwang, Kevin A T Silverstein, Scott M Dehm. Cancer Res 2013
445
9

A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.
James D Joseph, Nhin Lu, Jing Qian, John Sensintaffar, Gang Shao, Dan Brigham, Michael Moon, Edna Chow Maneval, Isan Chen, Beatrice Darimont,[...]. Cancer Discov 2013
375
9

ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.
Andrew J Armstrong, Russell Z Szmulewitz, Daniel P Petrylak, Jeffrey Holzbeierlein, Arnauld Villers, Arun Azad, Antonio Alcaraz, Boris Alekseev, Taro Iguchi, Neal D Shore,[...]. J Clin Oncol 2019
222
9

The mutational landscape of lethal castration-resistant prostate cancer.
Catherine S Grasso, Yi-Mi Wu, Dan R Robinson, Xuhong Cao, Saravana M Dhanasekaran, Amjad P Khan, Michael J Quist, Xiaojun Jing, Robert J Lonigro, J Chad Brenner,[...]. Nature 2012
9

ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer.
Laura Cato, Jonas de Tribolet-Hardy, Irene Lee, Jaice T Rottenberg, Ilsa Coleman, Diana Melchers, René Houtman, Tengfei Xiao, Wei Li, Takuma Uo,[...]. Cancer Cell 2019
68
13

Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer.
Matti Annala, Gillian Vandekerkhove, Daniel Khalaf, Sinja Taavitsainen, Kevin Beja, Evan W Warner, Katherine Sunderland, Christian Kollmannsberger, Bernhard J Eigl, Daygen Finch,[...]. Cancer Discov 2018
215
9

Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer.
Akash Kumar, Ilsa Coleman, Colm Morrissey, Xiaotun Zhang, Lawrence D True, Roman Gulati, Ruth Etzioni, Hamid Bolouri, Bruce Montgomery, Thomas White,[...]. Nat Med 2016
389
9

Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer.
Philip A Watson, Vivek K Arora, Charles L Sawyers. Nat Rev Cancer 2015
606
8

Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells.
Wendy Onstenk, Anieta M Sieuwerts, Jaco Kraan, Mai Van, Annemieke J M Nieuweboer, Ron H J Mathijssen, Paul Hamberg, Hielke J Meulenbeld, Bram De Laere, Luc Y Dirix,[...]. Eur Urol 2015
183
8

The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients.
Marzia Del Re, Elisa Biasco, Stefania Crucitta, Lisa Derosa, Eleonora Rofi, Cinzia Orlandini, Mario Miccoli, Luca Galli, Alfredo Falcone, Guido W Jenster,[...]. Eur Urol 2017
144
8

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Johann Sebastian de Bono, Stephane Oudard, Mustafa Ozguroglu, Steinbjørn Hansen, Jean-Pascal Machiels, Ivo Kocak, Gwenaëlle Gravis, Istvan Bodrogi, Mary J Mackenzie, Liji Shen,[...]. Lancet 2010
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.